Tanomastat

Drug Profile

Tanomastat

Alternative Names: BAY 12 9566

Latest Information Update: 20 Nov 2000

Price : $50

At a glance

  • Originator Bayer
  • Developer Bayer; National Cancer Institute (Canada)
  • Class Antineoplastics; Butyric acids; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Osteoarthritis; Ovarian cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 20 Nov 2000 Results of a phase III study in patients with ovarian cancer have been added to the adverse events and Cancer therapeutic trials section
  • 23 May 2000 BAY 129566 is now called tanomastat (INN)
  • 07 Mar 2000 A clinical study in patients with solid tumours has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top